Published in Radiother Oncol on August 23, 2007
The concept and evolution of involved site radiation therapy for lymphoma. Int J Clin Oncol (2015) 1.40
Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.06
The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol (2010) 0.93
FDG PET/CT in children and adolescents with lymphoma. Pediatr Radiol (2013) 0.85
Respiratory gated [18F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases. Strahlenther Onkol (2012) 0.85
Evolution of the techniques of radiation therapy in the management of lymphoma. Int J Clin Oncol (2013) 0.84
Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma. Adv Hematol (2010) 0.82
Application of metabolic PET imaging in radiation oncology. Radiat Res (2012) 0.82
Biologically conformal treatment: biomarkers and functional imaging in radiation oncology. Future Oncol (2008) 0.79
Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease. Radiat Oncol (2013) 0.77
FDG-PET scan and treatment planning for early stage Hodgkin lymphoma. Radiother Oncol (2007) 0.75
Tailored strategies for radiation therapy in classical Hodgkin's lymphoma. Crit Rev Oncol Hematol (2012) 0.75
Patterns of failure of diffuse large B‑cell lymphoma patients after involved-site radiotherapy. Strahlenther Onkol (2017) 0.75
Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol (2008) 2.23
Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol (2008) 2.23
Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol (2006) 1.97
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol (2003) 1.43
Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer (2003) 1.24
Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol (2005) 1.18
Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab (2007) 1.16
Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging (2007) 1.08
Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys (2005) 1.05
Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer (2009) 1.01
Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol (2009) 1.00
Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology (2010) 0.95
18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 0.91
Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid (2012) 0.91
Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (2011) 0.91
Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy. Eur J Radiol (2007) 0.89
Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer (2007) 0.88
IMRT or conformal radiotherapy for adjuvant treatment of retroperitoneal sarcoma? Radiother Oncol (2011) 0.87
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer (2011) 0.87
Radiotherapy of hodgkin lymphoma: indications, new fields, and techniques. Semin Radiat Oncol (2007) 0.87
Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys (2011) 0.87
Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study. Ann Surg (2012) 0.86
F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res (2007) 0.84
Cannon ball lucencies from last century: lucite balls used to treat pulmonary tuberculosis. Indian J Chest Dis Allied Sci (2010) 0.84
Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials. J Nucl Med (2012) 0.84
6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data. Mol Imaging Biol (2006) 0.83
The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol (2008) 0.82
The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. Eur J Cancer (2008) 0.80
Ceftriaxone monotherapy for the treatment of febrile neutropenia in patients with solid tumors: a prospective study of 100 episodes. Med Sci Monit (2004) 0.79
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res (2005) 0.78
Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab (2010) 0.78
Sentinel node biopsy in early oral squamous cell carcinomas: a 10-year experience. Laryngoscope (2012) 0.78
Thyroid cancer patients treated with 131I: radiation dose to relatives after discharge from the hospital. Thyroid (2011) 0.78
Preoperative localization of neck recurrences from thyroid cancer: charcoal tattooing under ultrasound guidance. Thyroid (2015) 0.77
Correlation between [18f]fluorodeoxyglucose positron-emission tomography scan and histology of pelvic nodes in early-stage cervical cancer. Anticancer Res (2010) 0.77
Abnormal pelvic uptake on post-therapeutic radioiodine (131I) whole-body scan. Eur J Nucl Med Mol Imaging (2011) 0.75
[Positron emission tomography in digestive tract cancer]. Gastroenterol Clin Biol (2002) 0.75
Analysis of feasibility and toxicity of radiotherapy in centenarians. J Am Geriatr Soc (2013) 0.75
Frequency and intensity of pain related to thyroid nodule fine-needle aspiration cytology. Thyroid (2013) 0.75
Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients. Int J Radiat Oncol Biol Phys (2012) 0.75
[Positron emission tomography and gastrointestinal oncology]. Gastroenterol Clin Biol (2003) 0.75
Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy. Endocr Relat Cancer (2013) 0.75
[The sentinel lymph node in cancer of the breast: clinical aspects]. Bull Cancer (2003) 0.75